Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 1015550 pharmacokinetics in hepatic impairment
NCT05661344Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2023
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of nerandomilast (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration-time Curve of R-BI 1015550 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point at 144 hours and Maximum Measured Concentration of R-BI 1015550 in Plasma at 144 hours. Started Feb 2023; status: completed.
02
Drugs
nerandomilast
Beyond the preview
Go deeper on NCT05661344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05661344.